Vera Therapeutics Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Vera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $78. The average 1-year stock price forecast is 139.78% higher than the current stock price, while the lowest is $35 (+7.59%) and the highest is $110 (+238.15%).

Price Target: $78 (+139.78%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$35	$78	$82	$110
Change	+7.59%	+139.78%	+152.08%	+238.15%

Analyst Ratings

The average analyst rating for Vera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	11	11	12	12	12	12
Buy	1	1	1	1	1	1
Hold	2	2	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	14	14	14	14	14	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Pete Stavropoulos Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $100	Buy	Maintains	$100	+207.41%	Jun 5, 2026
Arthur He CFA H.C. Wainwright	H.C. Wainwright	Buy Maintains $110	Buy	Maintains	$110	+238.15%	Jun 5, 2026
Paul Choi Goldman Sachs	Goldman Sachs	Buy Maintains $90	Buy	Maintains	$90	+176.67%	Jun 3, 2026
Andy Chen Wolfe Research	Wolfe Research	Buy Maintains $88	Buy	Maintains	$88	+170.52%	Jun 3, 2026
Vamil Divan Guggenheim	Guggenheim	Buy Reiterates $56	Buy	Reiterates	$56	+72.15%	Jun 3, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

38.50M

Revenue Next Year

253.53M

from 38.50M

558.48%

from 38.50M

EPS This Year

-6.29

from -4.66

EPS Next Year

-3.80

from -6.29

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	38.50M
Operating Income	-34.40M	-90.90M	-102.01M	-167.17M	-315.47M	-454.66M
Net Income	-32.61M	-89.06M	-95.99M	-152.15M	-299.62M	-446.34M
EPS	-	-	-	-	-4.66	-6.29
Free Cash Flow	-20.38M	-42.37M	-58.02M	-84.35M	-139.02M	-336.58M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	73.6M
Avg	38.5M
Low	12.1M

Revenue Growth

Revenue Growth	2027	2028
High	1,222.7%
Avg	558.5%
Low	238.2%

EPS Forecast

EPS	2026	2027	2028
High	-5.56
Avg	-6.29
Low	-7.39

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-